HC Wainwright Has Negative Estimate for CRDL FY2025 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright reduced their FY2025 earnings per share estimates for Cardiol Therapeutics in a report released on Monday, April 7th. HC Wainwright analyst V. Bernardino now expects that the company will earn ($0.47) per share for the year, down from their prior forecast of ($0.33). HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01.

A number of other research firms also recently issued reports on CRDL. RODMAN&RENSHAW upgraded shares of Cardiol Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of Cardiol Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $7.00 price objective on the stock. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $8.40.

Remove Ads

Cardiol Therapeutics Trading Up 7.6 %

Shares of NASDAQ:CRDL traded up $0.07 during midday trading on Thursday, reaching $1.03. The company's stock had a trading volume of 191,992 shares, compared to its average volume of 384,281. Cardiol Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $3.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49. The firm has a 50 day moving average price of $1.11 and a two-hundred day moving average price of $1.42. The firm has a market capitalization of $85.09 million, a price-to-earnings ratio of -2.64 and a beta of 1.00.

Institutional Investors Weigh In On Cardiol Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp bought a new stake in Cardiol Therapeutics during the 4th quarter worth approximately $25,000. Jane Street Group LLC bought a new stake in Cardiol Therapeutics during the third quarter worth $29,000. Cetera Investment Advisers purchased a new stake in Cardiol Therapeutics in the 4th quarter valued at $56,000. Virtu Financial LLC bought a new position in Cardiol Therapeutics during the 4th quarter valued at $61,000. Finally, Atria Investments Inc purchased a new position in Cardiol Therapeutics during the 4th quarter worth $174,000. 12.49% of the stock is owned by institutional investors.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.